Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 1
1955 2
1956 2
1957 2
1965 2
1966 3
1967 2
1968 6
1969 5
1970 4
1971 6
1972 6
1973 8
1974 13
1975 90
1976 79
1977 76
1978 72
1979 84
1980 65
1981 105
1982 93
1983 128
1984 138
1985 156
1986 153
1987 140
1988 171
1989 167
1990 198
1991 219
1992 210
1993 238
1994 300
1995 299
1996 374
1997 364
1998 415
1999 400
2000 461
2001 481
2002 482
2003 566
2004 597
2005 622
2006 712
2007 680
2008 759
2009 784
2010 827
2011 817
2012 918
2013 1009
2014 1026
2015 935
2016 1037
2017 1092
2018 1065
2019 1097
2020 1176
2021 1083
2022 973
2023 866
2024 374

Text availability

Article attribute

Article type

Publication date

Search Results

22,543 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Lesion by Focality"
Page 1
Clinical development and potential of photothermal and photodynamic therapies for cancer.
Li X, Lovell JF, Yoon J, Chen X. Li X, et al. Nat Rev Clin Oncol. 2020 Nov;17(11):657-674. doi: 10.1038/s41571-020-0410-2. Epub 2020 Jul 22. Nat Rev Clin Oncol. 2020. PMID: 32699309 Review.
Two main approaches are available: photodynamic therapy, which results in localized chemical damage in the target lesions, and photothermal therapy, which results in localized thermal damage. ...Over the past decades, great strides have been made in the devel …
Two main approaches are available: photodynamic therapy, which results in localized chemical damage in the target lesions, and …
Inflammation and neuroprotection in traumatic brain injury.
Corps KN, Roth TL, McGavern DB. Corps KN, et al. JAMA Neurol. 2015 Mar;72(3):355-62. doi: 10.1001/jamaneurol.2014.3558. JAMA Neurol. 2015. PMID: 25599342 Free PMC article. Review.
Central nervous system resident and peripherally derived inflammatory cells respond to TBI and can provide neuroprotection or participate in maladaptive secondary injury reactions. The exact contribution of inflammatory cells to a TBI lesion is dictated by their anatomical …
Central nervous system resident and peripherally derived inflammatory cells respond to TBI and can provide neuroprotection or participate in …
The role of BRAF V600 mutation in melanoma.
Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. Ascierto PA, et al. J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85. J Transl Med. 2012. PMID: 22554099 Free PMC article.
Among who continued vemurafenib >30 days after local therapy of PD lesion(s), a median overall survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients who did not continue treatment, median o …
Among who continued vemurafenib >30 days after local therapy of PD lesion(s), a median overall survival was not reac …
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Fendler WP, et al. JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096. JAMA Oncol. 2019. PMID: 30920593 Free PMC article. Clinical Trial.
CONCLUSIONS AND RELEVANCE: Using blinded reads and independent lesion validation, we establish high PPV for 68Ga-PSMA-11 PET, detection rate and interreader agreement for localization of recurrent prostate cancer. TRIAL REGISTRATION: ClinicalTrials.gov identi …
CONCLUSIONS AND RELEVANCE: Using blinded reads and independent lesion validation, we establish high PPV for 68Ga-PSMA-11 PET, detecti …
Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.
Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H, Howell MD, Kirby JS. Alavi A, et al. Br J Dermatol. 2022 May;186(5):803-813. doi: 10.1111/bjd.20969. Epub 2022 Mar 6. Br J Dermatol. 2022. PMID: 34978076 Free PMC article.
BACKGROUND: Janus kinase (JAK)-mediated cytokine signalling contributes to local and systemic inflammation in hidradenitis suppurativa (HS). ...METHODS: Patients received open-label INCB054707 15 mg once daily (QD; Study 1) or were randomized to INCB054707 30, 60 or …
BACKGROUND: Janus kinase (JAK)-mediated cytokine signalling contributes to local and systemic inflammation in hidradenitis suppurativ …
Targeted phototherapy.
Mysore V, Shashikumar BM. Mysore V, et al. Indian J Dermatol Venereol Leprol. 2016 Jan-Feb;82(1):1-6. doi: 10.4103/0378-6323.172902. Indian J Dermatol Venereol Leprol. 2016. PMID: 26728802 Free article. Review.
CONCLUSIONS AND RECOMMENDATIONS: All forms of targeted phototherapy are useful in vitiligo. Good responses were seen in localized involvement, resistant lesions and in children in whom their use is more accepted and convenient (Level of evidence 2+, Grade of recomme …
CONCLUSIONS AND RECOMMENDATIONS: All forms of targeted phototherapy are useful in vitiligo. Good responses were seen in localized inv …
Peripheral arterial disease.
Ouriel K. Ouriel K. Lancet. 2001 Oct 13;358(9289):1257-64. doi: 10.1016/S0140-6736(01)06351-6. Lancet. 2001. PMID: 11675083 Review.
The choice of the intervention is dependent on the anatomy of the stenotic or occlusive lesion; percutaneous interventions are appropriate when the lesion is focal and short but longer lesions must be treated with surgical revascularisation to achieve …
The choice of the intervention is dependent on the anatomy of the stenotic or occlusive lesion; percutaneous interventions are approp …
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Koole S, et al. Int J Gynecol Cancer. 2020 Jun;30(6):888-892. doi: 10.1136/ijgc-2020-001231. Epub 2020 Mar 23. Int J Gynecol Cancer. 2020. PMID: 32205449 Free PMC article.
STUDY HYPOTHESIS: We hypothesize that the addition of HIPEC to primary cytoreductive surgery improves overall survival in patients with primary FIGO stage III epithelial ovarian cancer. TRIAL DESIGN: This international, randomized, open-label, phase III trial …
STUDY HYPOTHESIS: We hypothesize that the addition of HIPEC to primary cytoreductive surgery improves overall survival in patients with prim …
Central Endoscopy Reading in Inflammatory Bowel Diseases.
Panés J, Feagan BG, Hussain F, Levesque BG, Travis SP. Panés J, et al. J Crohns Colitis. 2016 Sep;10 Suppl 2:S542-7. doi: 10.1093/ecco-jcc/jjv171. J Crohns Colitis. 2016. PMID: 27604978 Review.
Endoscopic assessment of the presence and severity of endoscopic lesions has become an essential part of clinical trials in ulcerative colitis and Crohn's disease, for both patient eligibility and outcome measures. Variability in lesion interpretation between …
Endoscopic assessment of the presence and severity of endoscopic lesions has become an essential part of clinical trials in ul …
Alfimeprase.
[No authors listed] [No authors listed] Drugs R D. 2008;9(3):185-90. doi: 10.2165/00126839-200809030-00006. Drugs R D. 2008. PMID: 18457471
The primary endpoint of the NAPA-2 trial was the avoidance of surgery within 30 days of treatment with alfimeprase, whilst the SONOMA-2 trial's endpoint was the restoration of function at 15 minutes after dosing. ...In the SONOMA-2 trial, alfimeprase restored …
The primary endpoint of the NAPA-2 trial was the avoidance of surgery within 30 days of treatment with alfimeprase, whilst the SONOMA …
22,543 results
You have reached the last available page of results. Please see the User Guide for more information.